Lilly’s Zepbound Cuts Risk of Diabetes episode artwork

EPISODE · Aug 20, 2024 · 42 MIN

Lilly’s Zepbound Cuts Risk of Diabetes

from Bloomberg Intelligence · host Bloomberg

Watch Alix and Paul LIVE every day on YouTube: http://bit.ly/3vTiACF. Sam Fazeli, Bloomberg Intelligence, Director of Research for Global Industries and Senior Pharmaceuticals, discusses how Eli Lilly’s drug Zepbound, cuts the risk of diabetes. Craig Trudell, Bloomberg Global Autos Editor, discusses the European Union saying it plans to introduce an additional 9% tariff on Teslas imported from China. Dryden Pence, CIO at Pence Wealth Management, joins to discuss his outlook for the markets. Henri Pierre-Jacques, Co-founder & Managing Partner, at Harlem Capital Partners, discusses current investments in AI. Katerina Simonetti, Senior Vice President, Private Wealth Advisor of Morgan Stanley Private Wealth Management, discusses her outlook on the markets, investing.Hosts: Paul Sweeney and Alix SteelSee omnystudio.com/listener for privacy information.

Episode metadata supplied by the publisher feed · Published Aug 20, 2024

Embed this episode

NOW PLAYING

Lilly’s Zepbound Cuts Risk of Diabetes

0:00 42:44

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Bloomberg Intelligence?

This episode is 42 minutes long.

When was this Bloomberg Intelligence episode published?

This episode was published on August 20, 2024.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this Bloomberg Intelligence episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!